Lattice_grid_med
Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term PHASE-II TRIAL. Found 10 abstracts

Bilusic M, Wong YN. Anti-angiogenesis in prostate cancer: knocked down but not out. Asian journal of andrology. 2014 May;16(3):372-7.   PMCID: PMC4023362
Jansen K, Heirbaut L, Verkerk R, Cheng JD, Joossens J, Cos P, Maes L, Lambeir AM, De Meester I, Augustyns K, Van der Veken P. Extended Structure Activity Relationship and Pharmacokinetic Investigation of (4-Quinolinoyl)glycy1-2-cyanopyrrolidine Inhibitors of Fibroblast Activation Protein (FAP). Journal of medicinal chemistry. 2014 Apr;57(7):3053-74.
Pond GR, Agarwal N, Bellmunt J, Choueiri TK, Qu A, Fougeray R, Vaughn D, James ND, Salhi Y, Albers P, Niegisch G, Galsky MD, Wong YN, Ko YJ, Stadler WM, O'Donnell PH, Sridhar SS, Vogelzang NJ, Necchi A, Di Lorenzo G, Sternberg CN, Mehta A, Sonpavde G. A nomogram including baseline prognostic factors to estimate the activity of second-line therapy for advanced urothelial carcinoma. BJU international. 2014 May;113(5B):E137-E143.
Lo PC, Chen J, Stefflova K, Warren MS, Navab R, Bandarchi B, Mullins S, Tsao M, Cheng JD, Zheng G. Photodynamic Molecular Beacon Triggered by Fibroblast Activation Protein on Cancer-Associated Fibroblasts for Diagnosis and Treatment of Epithelial Cancers. Journal of medicinal chemistry. 2009 Jan;52(2):358-68.   PMCID: PMC2773291
Maximov PY, Lewis-Wambi JS, Jordan VC. The Paradox of Oestradiol-Induced Breast Cancer Cell Growth and Apoptosis. Current Signal Transduction Therapy. 2009 May;4(2):88-102.   PMCID: PMC2757321
Bukowski RM, Ozols RF, Markman M. The management of recurrent ovarian cancer. Seminars in Oncology. 2007 Apr;34(2):S1-S15.
Fujiwara K, Armstrong D, Morgan M, Markman M. Principles and practice of intraperitoneal chemotherapy for ovarian cancer. International Journal of Gynecological Cancer. 2007 Jan;17(1):1-20.
Gridelli C, Langer C, Maione P, Rossi A, Schild SE. Lung cancer in the elderly. Journal of Clinical Oncology. 2007 May;25(14):1898-907.
Khazak V, Astsaturov I, Serebriiskii IG, Golemis EA. Selective Raf inhibition in cancer therapy. Expert Opinion on Therapeutic Targets. 2007 Dec;11(12):1587-609.
Trotti A, Pajak TF, Gwede CK, Paulus R, Cooper J, Forastiere A, Ridge JA, Watkins-Bruner D, Garden AS, Ang KK, Curran W. TAME: development of a new method for summarising adverse events of cancer treatment by the Radiation Therapy Oncology Group. Lancet Oncology. 2007 Jul;8(7):613-24.
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term PHASE-II TRIAL

PHASE-II TRIAL CLINICAL-TRIALS GYNECOLOGIC-ONCOLOGY-GROUP ADJUVANT CHEMOTHERAPY RANDOMIZED-TRIAL CHEMOTHERAPY RADIOTHERAPY SERINE-PROTEASE Urology & Nephrology HIGH-DOSE CARBOPLATIN intraperitoneal chemotherapy prostate cancer PLATINUM-CONTAINING RANDOMIZED COLON-CANCER CELL LUNG-CANCER CISPLATIN-BASED CHEMOTHERAPY CLEAVING ENZYME ESTROGEN-RECEPTOR-ALPHA TYROSINE KINASE INHIBITOR Andrology THERAPY nomogram 5132 CGP 69846A TOXICITY GEMCITABINE PLUS VINORELBINE METASTATIC COLORECTAL-CANCER selective oestrogen receptor modulators STAGE-IV MELANOMA PROLYL OLIGOPEPTIDASE response rate kinase inhibitor PACLITAXEL combination therapy VINFLUNINE SURGICAL ADJUVANT BREAST REMODELING INTERFACE SELECTIVE REGIMEN ADVANCED HEAD PROGRESSION-FREE SURVIVAL REFRACTORY OVARIAN TYROSINE KINASE angiogenesis BREAST-CANCER COMPLETE RESPONSE STROMAL FIBROBLASTS tamoxifen ANTIAPOPTOTIC SINGLE GROUP TERM-FOLLOW-UP THORACIC PRIMARY PERITONEAL TRANSITIONAL-CELL CARCINOMA MEK clinical trials LEUKEMIA GROUP-B QUALITY-OF-LIFE progression-free survival at CARCINOMA ATHYMIC MICE ADVANCED SOLID TUMORS B-Raf C-RAF CLINICAL-TRIAL Medicinal Chemistry Breast cancer MONOCLONAL-ANTIBODY ANTITUMOR-ACTIVITY transduction PROGESTERONE-RECEPTOR SYSTEMIC CHEMOTHERAPY INHIBITORS apoptosis advanced urothelial cancer PAPILLARY THYROID-CARCINOMA signal TUMOR-GROWTH cancer TRIAL TRACT Ras ACUTE GROUP RTOG oestrogen receptor DOSE-ESCALATION ENDOTHELIAL GROWTH-FACTOR NECK-CANCER STIMULATING FACTOR SUPPORT SQUAMOUS-CELL CARCINOMAS BCL-2-FAMILY PROTEINS THERAPY AGENT INTRAVENOUS CISPLATIN GROWTH-FACTOR RECEPTOR ONCOLOGY-GROUP NEOPLASM STAGE-III ovarian cancer oestrogen action TAMOXIFEN RESISTANCE C-RAF-1 TUMOR STROMAL FIBROBLASTS c-RAF-1 LOW-DOSE CARBOPLATIN COMBINATION CHEMOTHERAPY antisense inhibitor systems biology EPITHELIAL CANCERS ALPHA-FOLATE RECEPTOR MYELOID-LEUKEMIA PEPTIDASE-IV INHIBITORS MATRIX METALLOPROTEINASES DOUBLE-BLIND PLUS PREDNISONE CANCER DIPEPTIDYL PEPTIDASE CARBOPLATIN-BASED CHEMOTHERAPY CISPLATIN-BASED THERAPY CYSTEINE-RICH DOMAIN 6 months ANTISENSE OLIGONUCLEOTIDE second-line therapy epidermal growth factor COMBINED-MODALITY SMALL-MOLECULE INHIBITOR
Last updated on Thursday, April 02, 2020